22 December 2024NewsAmericasPaul Inman Partner Gowling WLG
WATCH: Jurisdictional overreach of foreign courts in patent disputes
Long-recognised, unwritten jurisdictional norms have seen questions of validity and infringement of registered IP rights reserved to the courts of the country of registration. However, recent attempts have been made by litigants and courts in China, and more recently by commentators and litigants in Europe, to exert extra-territorial jurisdiction in relation to patents. We look at what patentees and/or alleged infringers can do, whether in Europe or the US, to prevent overreach by a foreign court.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Atif Choudhury at achoudhury@lifesciencesipreview.com
2 July 2026 A federal court has ruled in a dispute between a clinical trial technology company and a psychedelic drug developer over allegations of trade secret misuse during a bidding process.
30 June 2026 Sandoz has filed FDA applications for generic versions of Eli Lilly’s blockbuster drugs, marking an early step towards potential competition in the fast-growing GLP-1 market.
25 June 2026 The Federal Circuit has brought Paxlovid’s infringement case to an end, serving as a reminder that even minor changes to patent language can have major consequences.